Vircell Announces Immediate Release of COVID-19 Research Kit
By LabMedica International staff writers Posted on 05 Mar 2020 |
Image: The Vircell COVID-19 detection kit (Photo courtesy of Vircell)
An all-out R&D program carried out by the biotechnology company Vircell (Granada, Spain) has resulted in a PCR-based test for the detection of COVID-19.
A novel coronavirus of zoonotic origin, the 2019-nCoV virus (the causative agent of COVID-19 disease) was recently identified in patients with acute respiratory disease. This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city in China, but has subsequently been detected in other provinces of China as well as in major outbreaks in several other countries in Asia (South Korea, Thailand, Japan) and Europe (Italy). At this time nearly 80,000 cases of the disease have been confirmed with close to 3,000 fatalities.
Signs of infection are highly non-specific and these include respiratory symptoms, fever, cough, dyspnea, and viral pneumonia. Currently, experts estimate that only a small percentage of coronavirus cases have actually been diagnosed clinically. Therefore, diagnostic tests specific for this infection are urgently needed for confirming suspected cases, screening patients, and conducting virus surveillance.
In response to the potential pandemic spread of the virus, Vircell rapidly developed a product for detection of COVID-19 that is available right now for research use.
The new product generates fast and reliable results in 90 minutes and is suitable for use in any qPCR thermal cycler with (FAM/HEX) detection. It is a double-target assay, specific for COVID-19 and other coronaviruses related to SARS. The assay kit contains two lyophilized master mixes for virus detection and confirmation, as suggested by international guidelines.
The assay does not show cross reactions with other common human respiratory CoVs or MERS and includes an internal amplification control in each master mix.
Vircell, which has always been concerned and committed to respiratory infectious diseases in China, has now made a tremendous R&D effort to develop this novel product in order to contribute as much as possible to understanding and containing this highly contagious disease.
Related Links:
Vircell
A novel coronavirus of zoonotic origin, the 2019-nCoV virus (the causative agent of COVID-19 disease) was recently identified in patients with acute respiratory disease. This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city in China, but has subsequently been detected in other provinces of China as well as in major outbreaks in several other countries in Asia (South Korea, Thailand, Japan) and Europe (Italy). At this time nearly 80,000 cases of the disease have been confirmed with close to 3,000 fatalities.
Signs of infection are highly non-specific and these include respiratory symptoms, fever, cough, dyspnea, and viral pneumonia. Currently, experts estimate that only a small percentage of coronavirus cases have actually been diagnosed clinically. Therefore, diagnostic tests specific for this infection are urgently needed for confirming suspected cases, screening patients, and conducting virus surveillance.
In response to the potential pandemic spread of the virus, Vircell rapidly developed a product for detection of COVID-19 that is available right now for research use.
The new product generates fast and reliable results in 90 minutes and is suitable for use in any qPCR thermal cycler with (FAM/HEX) detection. It is a double-target assay, specific for COVID-19 and other coronaviruses related to SARS. The assay kit contains two lyophilized master mixes for virus detection and confirmation, as suggested by international guidelines.
The assay does not show cross reactions with other common human respiratory CoVs or MERS and includes an internal amplification control in each master mix.
Vircell, which has always been concerned and committed to respiratory infectious diseases in China, has now made a tremendous R&D effort to develop this novel product in order to contribute as much as possible to understanding and containing this highly contagious disease.
Related Links:
Vircell
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants